Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine augmentation of exposure therapy for pediatric specific phobia
ACTRN12612000420842Phase 2Recruiting
- Sponsor
- Dr Allison Waters
- Start
- Mar 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in specific phobia comparing D-cycloserine plus exposure therapy with Placebo plus exposure therapy (2 arms). Primary endpoints: Anxiety Disorders Interview Schedule (ADIS) - Child/Parent Versions and Children's Global Assessment Scale (CGAS). Started Mar 2012; status: recruiting.
02
Drugs
d-cycloserine
03
Conditions
specific phobia
Beyond the preview
Go deeper on ACTRN12612000420842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000420842.